BURLINGTON, Mass.--(BUSINESS WIRE)--Dyax Corp. (NASDAQ: DYAX) today announced financial results for the third quarter ended September 30, 2015. Dyax will host a webcast to review these results in conjunction with the Company’s Research and Development Day on Monday, November 2, 2015 at 8:00 a.m. (ET).
Recent highlights include:
• Protocol finalized with the U.S. Food and Drug Administration for Dyax’s single, pivotal Phase 3 clinical trial evaluating DX-2930 in hereditary angioedema (HAE);
Help employers find you! Check out all the jobs and post your resume.
